Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Sells $13,762.32 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Mark Lackner sold 4,411 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.12, for a total value of $13,762.32. Following the completion of the sale, the insider now owns 191,317 shares in the company, valued at $596,909.04. This trade represents a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock traded up $0.24 during trading hours on Friday, reaching $3.24. 1,591,780 shares of the company’s stock traded hands, compared to its average volume of 1,308,390. The firm has a market capitalization of $230.90 million, a price-to-earnings ratio of -1.30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The firm’s 50 day moving average is $3.33 and its 200-day moving average is $3.54.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in shares of Zentalis Pharmaceuticals by 15.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company’s stock valued at $1,365,000 after buying an additional 43,839 shares in the last quarter. Rhumbline Advisers raised its position in shares of Zentalis Pharmaceuticals by 13.8% during the second quarter. Rhumbline Advisers now owns 94,213 shares of the company’s stock worth $385,000 after purchasing an additional 11,451 shares during the period. Los Angeles Capital Management LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 117.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 83,717 shares of the company’s stock valued at $342,000 after purchasing an additional 45,249 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at about $95,000. Finally, Renaissance Technologies LLC grew its position in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.